We are live on ! Find out more
ACM

Aquilo Capital Management Portfolio holdings

AUM $55.8M
1-Year Est. Return 41.76%
This Fund
S&P 500
This Quarter Est. Return
+55.9%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$160M
AUM Growth
+$50.1M
Cap. Flow
-$16.4M
Cap. Flow %
-10.23%
Top 10 Hldgs %
100%
Holding
15
New
3
Increased
1
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
RPTX
Repare Therapeutics
RPTX
+$3.54M
2
KYMR icon
Kymera Therapeutics
KYMR
+$1.77M
3
STRO icon
Sutro Biopharma
STRO
+$1.33M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$8.05M
2
CCCC icon
C4 Therapeutics
CCCC
+$3.7M
3
SLN
Silence Therapeutics
SLN
+$3.02M
4
GMAB icon
Genmab
GMAB
+$1.84M
5
ARGX icon
argenx
ARGX
+$1.83M

Sector Composition

Rank Sector Weight
1 Healthcare 88.87%
2 Miscellaneous 11.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARWR icon
1
Arrowhead Research
ARWR
$9.33B
$27.8M 17.33%
908,474
– –
BPMC
2
DELISTED
Blueprint Medicines
BPMC
$23.5M 14.65%
254,827
-124,263
-33% -$8.05M
KYMR icon
3
Kymera Therapeutics
KYMR
$9.63B
$22.4M 13.98%
881,337
+99,118
+13% +$1.77M
ARVN icon
4
Arvinas
ARVN
$509M
$20.1M 12.55%
489,153
– –
SLN
5
Silence Therapeutics
SLN
$697M
$18.1M 11.29%
1,043,284
-268,949
-20% -$3.02M
XBI icon
6
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$17.9M 11.13%
+200,000
New +$14.9M
RGNX icon
7
Regenxbio
RGNX
$478M
$14.4M 8.98%
802,424
-45,000
-5% -$793K
MRUS
8
DELISTED
Merus
MRUS
$9.77M 6.09%
355,109
-75,000
-17% -$1.75M
RPTX
9
DELISTED
Repare Therapeutics
RPTX
$4.62M 2.88%
+633,271
New +$3.54M
STRO icon
10
Sutro Biopharma
STRO
$260M
$1.8M 1.12%
+42,065
New +$1.33M
ARGX icon
11
argenx
ARGX
$60.2B
– –
-3,715
Closed -$1.83M
CCCC icon
12
C4 Therapeutics
CCCC
$373M
– –
-1,990,334
Closed -$3.7M
GMAB icon
13
Genmab
GMAB
$21.4B
– –
-52,148
Closed -$1.84M
OLMA icon
14
Olema Pharmaceuticals
OLMA
$791M
– –
-88,875
Closed -$1.1M
PVLA
15
Palvella Therapeutics
PVLA
$2.1B
– –
-41,290
Closed -$984K

Similar funds

VCM
VeriStar Capital Management New York $54.7M AUM 2.08% 1-Year Est. Return
YEPV
Yorktown Energy Partners VIII New York $52.9M AUM 30% 1-Year Est. Return
HWP
Heritage Wealth Partners Dublin, Ohio $65.6M AUM 16.69% 1-Year Est. Return
GIS
Grayhawk Investment Strategies Calgary, Alberta, Canada $43.9M AUM 6.23% 1-Year Est. Return
AA
AlphaQ Advisors Winter Park, Florida $41.7M AUM 12.96% 1-Year Est. Return
PGIM
Pacific Global Investment Management Glendale, California $70.7M AUM 14.46% 1-Year Est. Return
RGMC
Revolution Growth Management Company Washington, District of Columbia $70.8M AUM 20.1% 1-Year Est. Return
PAM
Pamalican Asset Management Hong Kong $75.4M AUM

Aquilo Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Aquilo Capital Management held 15 positions worth $160M, up 45% from $110M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Aquilo Capital Management withdrew a net $16.4M in Q4 2023, closing 5 positions and reducing 4 holdings. Its most notable exit was C4 Therapeutics, an estimated $3.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Aquilo Capital Management opened a new position in Repare Therapeutics worth $4.62M.

  • Aquilo Capital Management's largest Q4 2023 buy was Repare Therapeutics: 633,271 shares worth $4.62M.
  • Aquilo Capital Management added most to Kymera Therapeutics in Q4 2023, an estimated $1.77M increase.
  • Aquilo Capital Management's biggest Q4 2023 reduction was Blueprint Medicines, cutting an estimated $8.05M.
  • Aquilo Capital Management fully exited C4 Therapeutics in Q4 2023, selling an estimated $3.7M.
  • Aquilo Capital Management's ten largest holdings make up 100% of its $160M portfolio in Q4 2023.
  • Aquilo Capital Management opened 3 new positions and closed 5 in Q4 2023.
  • Aquilo Capital Management's portfolio value rose 45% quarter-over-quarter to $160M.

Based on Aquilo Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.